Company / Cash & Equivalents
Viridian Therapeutics, Inc.\DE Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$874.7M
FY2025
5-year range
$197.0M / $874.7M
FY2021-FY2025
Trend
+21.9%
vs FY2024
Sector context
#21 of 207
Health Care
What the data says
Among 207 Health Care companies, Viridian Therapeutics, Inc.\DE is in the top 10% for cash & equivalents. Cash & Equivalents has increased for 6 consecutive years, from $27M in FY2019 to $875M in FY2025.
Based on SEC 10-K filings.
$875M in FY2025 with a 5-year CAGR of +47.0%. Top quartile in the Health Care sector.
Improved from $477M to $875M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +27.2%
- 5-Year CAGR
- +47.0%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 207This company $874.7M Sector average $669.5M
▼
+30.7% above sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's cash & equivalents has grown for 6 consecutive years.
- 5-year CAGR of +47.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 21.9% year-over-year.
- Ranks #21 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $874.7M | +21.9% |
| FY2024 | $717.6M | +50.3% |
| FY2023 | $477.4M | +12.4% |
| FY2022 | $424.6M | +115.5% |
| FY2021 | $197.0M | +54.4% |
| FY2020 | $127.6M | +376.1% |
| FY2019 | $26.8M | -17.8% |
| FY2018 | $32.6M | -31.3% |
| FY2017 | $47.4M | +114.6% |
| FY2016 | $22.1M | +4.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026